Stockscreener 앱 받기
16.95
1.68%
0.28
Pieris Pharmaceuticals Inc 주식(PIRS)의 최신 뉴스
How the (PIRS) price action is used to our Advantage - Stock Traders Daily
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire
(PIRS) Investment Analysis and Advice - Stock Traders Daily
Wayne-based Palvella Therapeutics Poised to Go Public Later This Year - VISTA.Today
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) - Yahoo Finance
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate - Yahoo Finance
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc.PIRS - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders - ForexTV.com
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of PIRS, ENV, GVP - AccessWire
Pieris Pharmaceuticals: Q2 Earnings Snapshot - San Antonio Express-News
Pieris Pharmaceuticals: Q2 Earnings Snapshot - mySA
Pieris Pharmaceuticals: Q2 Earnings Snapshot - CTPost
Pieris Pharmaceuticals: Q2 Earnings Snapshot - The Advocate
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS - ForexTV.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 Shares of Stock - Defense World
Adar1 capital management buys $92k worth of Pieris Pharmaceuticals stock - Investing.com
(PIRS) Long Term Investment Analysis - Stock Traders Daily
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Passes Above 50 Day Moving Average of $10.02 - Defense World
Global Chemotherapy Induced Anemia Drug Market 2024 Analysis by Top Key Players |SBI Pharmaceuticals Co. Ltd. - The NRI News
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders - Manchestertimes
Public Equity Report: Palvella lands on NASDAQ via Pieris merger - BioCentury
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders - Morningstar
General Mills, Inc. [GIS] gain 0.57% so far this year. What now? - The DBT News
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Business Wire
Viking Therapeutics stock (VKTX) could hit all time high and here’s why - BP Journal
Pieris Pharmaceuticals ($PIRS) and Palvella Therapeutics Announce Exciting Merger - BP Journal
Is today’s surge in Dermata Therapeutics (DRMA) justified ? - BP Journal
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders - PR Newswire
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings - Benzinga
PIRS Stock on the Rise: A Promising Investment - The InvestChronicle
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results - Benzinga
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today? - InvestorPlace
Ivey Business School Opens the Market to celebrate Women in Asset Management Program - The Bubble
Palvella and Pieris to merge - The Pharma Letter
Pieris Pharma stock surges on merger deal (NASDAQ:PIRS) - Seeking Alpha
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Crosses Below 50 Day Moving Average of $9.25 - Defense World
Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics - MarketWatch
Merger News Boosts Pieris (PIRS) Stock In Pre-Market Trading - Stocks Telegraph
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement - Yahoo Finance
Troutman Pepper Advises Palvella Therapeutics in Merger with Pieris Pharmaceuticals - Troutman Pepper
MEIP Stock sees a Significant Surge Amidst Strategic Evaluation - BP Journal
(PIRS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
StockNews.com Initiates Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - American Banking and Market News
StockNews.com Initiates Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30% - Simply Wall St
(PIRS) Technical Pivots with Risk Controls - Stock Traders Daily
Pieris loses Servier as partner for cancer immunotherapies - pharmaphorum
Pieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.com - Defense World
Pieris Pharma Says Servier Discontinues License Agreement - MarketWatch
Pieris Pharmaceuticals Faces Agreement Termination and Pursues New Opportunities - TipRanks
Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo New Zealand News
(PIRS) Proactive Strategies - Stock Traders Daily
StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Sport Australia
Pieris Pharmaceuticals Announces Presentation of In Vivo Preclinical Data for Its Lead Bispecific Immuno-Oncology ... - Yahoo Movies UK
Pieris Pharmaceuticals (NASDAQ:PIRS) Shares Cross Below 50-Day Moving Average of $11.26 - Defense World
Learn to Evaluate (PIRS) using the Charts - Stock Traders Daily
While institutions own 32% of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), individual investors are its largest ... - Yahoo New Zealand News
Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Don't? - Yahoo Movies UK
1.25%
1.94%
자본화:
|
볼륨(24시간):